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Abstract The structure of recombinant human cellular factor
XIII zymogen was solved in its monoclinic crystal form and
refined to an R-factor of 18.3% (Rfree = 23.6%) for all data
between 40.0 and 2.1 Aî resolution. Two non-proline cis peptide
bonds were detected. One is between Arg310 and Tyr311 close to
the active site cysteine residue (Cys314) and the other is between
Gln425 and Phe426 at the dimerization interface. The structure
and the role of these cis peptides are discussed in the light of their
possible importance for factor XIII function.
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1. Introduction
Plasma factor XIII (pFXIII) is the last enzyme in the blood
coagulation cascade and in contrast to all other enzymes in-
volved, it is not a serine protease but a transglutaminase,
catalyzing the formation of isopeptide bonds between the
side chains of glutamine and lysine residues. Its main role is
to stabilize the ¢brin soft clot, and to render it insusceptible to
¢brinolysis either by crosslinking of ¢brin itself or by cross-
linking K2-antiplasmin, a potent inhibitor of the protease plas-
min, onto the ¢brin clot [1^3].
De¢ciencies in factor XIII can be either acquired or inher-
ited. They inevitably lead to a prolonged coagulation time and
to increased occurrence of late bleeding. Furthermore, wound
healing disorders have been reported in connection with de-
creased pFXIII levels [4]. The ability of the enzyme to stabi-
lize blood clots may also have a negative impact. Under cer-
tain conditions, the unwanted formation of stabilized clots
carries the risk of thrombosis, making it desirable to develop
speci¢c factor XIII inhibitors for patients with a high risk of
thrombosis.
Factor XIII is found in various tissues and cells. The plas-
ma enzyme exists as an A2B2 heterotetramer of a total mo-
lecular weight of 320 kDa. A cellular form of factor XIII
(cFXIII) has been identi¢ed in platelets and monocytes/mac-
rophages. This form exists as a homodimer of two A subunits
of 731 amino acids each, with a total molecular weight of 166
kDa.
Activation of factor XIII occurs via proteolysis by the ser-
ine protease thrombin in the presence of calcium. Thrombin
cleaves a scissile peptide bond between Arg37 and Gly38. The
activation peptide (residue 1^37) is then thought to dissociate
from the protein, thus activating it.
The cellular factor XIII zymogen has been crystallized in
two di¡erent crystal forms [5] and its structure has been
solved in the orthorhombic crystal form (PDB code 1GGT,
[6]). Recently, the structure of thrombin-cleaved factor XIII
has been reported (PDB code 1FIE, [7]). The enzyme has been
described in terms of its domain structure and active site
geometry [8]. Both of these structure determinations were at
medium resolution (Table 1). We have determined the struc-
ture of recombinant cFXIII zymogen at high resolution (2.1
Aî ) in the monoclinic crystal form and describe some structur-
al details that may be important for the function of the mol-
ecule.
2. Materials and methods
Recombinant cFXIII was crystallized following the procedure of
Hilgenfeld et al. [5] using the hanging drop technique. 2 Wl of protein
solution at 2^4 mg/ml were mixed with 2 Wl of reservoir solution on a
siliconized cover slip and equilibrated against 1 ml of reservoir con-
taining 100 mM MES pH 6.2^6.4 and 1^2% (w/v) PEG-6000. Crystals
appeared within one week and continued to grow for a period of two
more weeks up to a maximum size of 0.5 mm in each dimension.
Sometimes, protein precipitate appeared ¢rst and then dissolved again
slowly while the crystals were growing.
The crystals were of the monoclinic space group P21 with unit cell
dimensions a = 134.59 Aî , b = 72.78 Aî , c = 101.05 Aî and L= 106.08‡.
With two molecules of 83 kDa each per asymmetric unit the Mat-
thews parameter [9] was 2.86 Aî 3/Da, and the solvent content 57%.
The di¡raction limit observed was about 2.3 Aî using our laboratory
source and about 1.9 Aî at a synchrotron source.
Crystals were mounted in glass capillaries and subjected to X-ray
analysis. Data were collected from two crystals at room temperature
on a Nonius FR591 rotating anode generator operated at 40 kV and
100 mA. The CuKK radiation was monochromatized using a graphite
monochromator and the data were recorded on a 30-cm MAR imag-
ing plate. Images were processed using DENZO and scaled using
SCALEPACK [10]. Due to the radiation sensitivity of the crystals it
was not possible to collect a full dataset from one crystal.
Data from three more crystals were collected at the synchrotron
beamline X11 at the EMBL outstation (DESY, Hamburg) at a wave-
length of 0.91 Aî , also at room temperature. The detector used was a
30-cm MAR imaging plate as well and the data were processed with
DENZO and scaled and merged with the data measured in our labo-
ratory using SCALEPACK. Statistics on data collection, processing
and scaling are given in Table 2. The data set was of good quality
as shown by the overall redundancy of about 3.3 and the conven-
tional merging R-factor, as well as by the redundancy-independent
merging R-factor and the precision-indicating merging R-factor
[11,12].
The structure was solved using the molecular replacement method
implemented in the program XPLOR [13]. The search model was one
subunit of the orthorhombic form of factor XIII zymogen (entry
1GGT from the PDB [14], see also Table 1) since at the time the
entry 1FIE was not available. For the rotation function data from
15^3.5 Aî resolution were used, and a Patterson vector length of 3.5 to
45 Aî . From the top ten peaks two solutions that were 180 degrees
apart from each other, were identi¢ed indicating the orientation of the
two molecules in the asymmetric unit. Translation functions in the
resolution range 10^3.0 Aî yielded highest peaks of 23.6 c and 15.9 c
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for the two molecules. A combined translation function established
the relative position of the two molecules with respect to one another.
The initial R-factor after correctly orienting and positioning the two
molecules was 33.8% for all data from 10 to 3.0 Aî resolution and it
was reduced to 32% after a total of 30 cycles of rigid body re¢nement.
The molecular replacement solution was con¢rmed using a di¡erence
Fourier calculation against a KAuCl4 derivative data set, which
showed metal binding sites on Cys188 and Cys423 of both molecules
as the highest peaks.
Model building was carried out with the program O [15] and re¢ne-
ment was done using XPLOR Version 3.1 [13].
After many rounds of manual rebuilding and re¢nement at gradu-
ally increasing resolution, the re¢nement converged at an R-factor of
18.3% (Table 2). All low resolution data to 40.0 Aî were included as
well as a bulk solvent correction [16] and no amplitude cuto¡ was
applied to the data. Throughout the re¢nement, non-crystallographic
symmetry restraints were maintained for the parts of the structure
that are neither involved in nor close to crystal contacts. In order
to avoid over¢tting of the model, each step of the rebuilding proce-
dure was closely monitored using the free R-factor and a residue real
space correlation coe⁄cient as a guide.
Accessible surface areas were computed using the program DSSP
[17].
Domain-domain interaction free energies were computed based on
atomic solvation parameters described by Eisenberg and McLachlan
[18]. All the free energy values given are standard-state free energy
values.
Sequence searches and comparisons were performed with the GCG
program package [19]. The Swissprot protein sequence data base
used was release version 34.0 as of November 1996. The search was
performed with the program FASTA [20] using the factor XIII
sequence 197^503, which constitutes the catalytic or core domain, as
the probe.
The coordinates and structure factors, upon which this work is
based, have been deposited in the Brookhaven Protein Data Base
and will be available under the accession code 1F13.
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Table 1
Structural data on FXIII in the PDB [14]
Structure PDB code Resolution (Aî ) # refs R (%) Rfree (%) Data cuto¡ [F/c(F)]
FXIII zymogen [6] 1GGT 10^2.65 65 937 21.6 n.r.a s 2.0
FXIII, thrombin-cleaved [7] 1FIE 10^2.50 49 681 18.2 n.r. s 2.0
an.r., not reported.
Fig. 1. Overall structure of the factor XIII dimer. The position of the local twofold axis is indicated by (). Within one subunit, the four do-
mains are coloured in yellow, red, green and blue, respectively. The sites of the cis peptide bonds are emphasized by *. The ¢gure was pro-
duced using the program MOLSCRIPT [28].
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3. Results
Some data on the re¢nement are summarized in Table 2.
The re¢ned structure consists of 11 556 non-hydrogen protein
atoms comprising residues 5^36 and 39^728 in subunit 1 and
6^36 and 41^728 in subunit 2, as well as 487 solvent atoms.
Almost all of the structure is in well de¢ned electron density
except for the terminal residues of the activation peptide and a
loop connecting domains 2 and 3. The overall R-factor based
on all data from 40 to 2.1 Aî resolution is indicative of a well
re¢ned structure. A Luzzati plot [21] indicated a coordinate
error of about 0.25 Aî (data not shown).
The structure of the whole dimer is shown in Fig. 1. One
subunit consists of four domains, which are colored di¡erently
in Fig. 1. The two subunits are related by a proper non-crys-
tallographic twofold axis. For all atoms of the structure, for
which non-crystallographic symmetry restraints were kept
in the re¢nement, the r.m.s. deviation between the two mole-
cules is 0.21 Aî , which is in the range of the overall coordinate
error.
The domain structure of factor XIII has been described
previously [6]. Based on secondary structural analysis we de-
lineate the domains in the following way: the activation pep-
tide runs from residues 1 to 37, domain 1 from 38 to 185,
domain 2 from 197 to 503, domain 3 from 517 to 628 and
domain 4 from 632 to 731. The sequence stretches in between
are the connecting loops between the domains. From the
structural point of view it might be advantageous to dissect
domain 2 into two di¡erent domains, one containing just the
three-stranded L-sheet seen in the bottom part of Fig. 1. To be
consistent with the previous literature we refrained from doing
so at that point.
Domain 1 contains almost exclusively L-sheet structure.
Two four-stranded L-sheets form an open barrel. In contrast
to earlier descriptions, the 37 amino acid long activation pep-
tide does extend this barrel by forming a ¢ve residue long L-
strand connected to the C-terminal L-strand of the barrel in
an antiparallel fashion. A total of 25 direct and at least four
water-mediated hydrogen bonds and salt bridges anchor the
peptide to the surface of the molecule, its main interactions
being to domains 1 and 2 of subunit 1 and domains 2 and 3 of
subunit 2 of the dimer. The interaction of the activation pep-
tide with the dimer buries a total of 3700 Aî 2 of surface on the
peptide and on both subunits. The total interaction energy
between the activation peptide and the rest of the dimer based
on atomic solvation parameters is approximately 314 kcal/
mol. From these about 39 kcal/mol account for interactions
with subunit 1 and the rest for interactions with subunit 2.
Domains 3 and 4 are both of the ¢bronectin III type. They
contain seven L-strands and are topologically identical. Both
domains interact closely with domain 2. In the interaction of
domain 2 with domain 3 a total surface area of 3000 Aî 2 is
buried; between domains 2 and 4 this value is 1900 Aî 2, and
between domains 3 and 4 it is 600 Aî 2. Energetically, the in-
teraction between domains 2 and 3 yields about 311 kcal/mol
of free energy, the one between domains 2 and 4 about 33
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Fig. 2. (2Fo-Fc)-electron density of the regions Arg310^Tyr311 (A) and Gln425^Phe426 (B). The calculated amplitudes and phases for the map are
based on a coordinate set that contains trans peptide bonds at these sites (shown in dotted lines). The maps are contoured at 1.2 c (A) and 1.5
c (B), respectively. The superimposed structures are the model before a cis peptide bond was introduced (dotted lines), and the re¢ned model
(solid lines). Shown are the sequence stretches 309^312 and 424^427 with only the main-chain atoms for the terminal residues and all atoms
for the residues £anking the cis peptide bond. Only density around the atoms of the residues 310^311 and 425^426 is displayed. It is clearly
evident that the model ¢ts the electron density map better when a cis peptide bond is present.
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kcal/mol and the one between domains 3 and 4 about 35
kcal/mol.
Domain 2 consists of a central six-stranded L-sheet, a sec-
ond L-sheet of three strands, a long L-hairpin and a total of
nine K-helical segments. The longest K-helix of 17 residues in
the center of the molecule contains the active site cysteine,
Cys314. The other two members of the catalytic triad, His373
and Asp396, are located on adjacent strands of the central six-
stranded L-sheet. During the course of the re¢nement it be-
came evident that two of the peptide bonds in this domain
(Arg310^Tyr311 and Gln425^Phe426) had to be rebuilt in the cis
conformation. Locally we observed rather large deviations
from ideal geometry and in a (Fo3Fc) di¡erence Fourier syn-
thesis, di¡erence density appeared next to the main chain
atoms. As shown in Fig. 2, it is clearly evident that a cis
peptide bond ¢tted better to the (2Fo-Fc) density than a trans
peptide bond. The interpretation was also con¢rmed by an
increase in the real space correlation coe⁄cient for the £ank-
ing residues upon modelling the cis conformation.
The sites of these non-proline cis peptide bonds in the struc-
ture are in the loop before the central helix that contains the
active site Cys314 at its N-terminus, and in a loop between two
K-helices close to the dimerization interface. Geometrically
there seems to be no obvious need for a cis peptide bond at
these sites as for instance a sharp change in chain direction
might require. Also, none of the residues £anking the cis
peptide are outliers with respect to their main chain dihedral
angles. As a matter of fact, all of them are in the L-region of
the Ramachandran plot [22].
Stabilization for the energetically unfavoured cis conforma-
tion comes from two di¡erent sources, hydrogen bonding and
hydrophobic side-chain interactions. As depicted in Fig. 3A,
Val287 forms hydrogen bonds with Tyr311-N as well as with
Arg310-O. The neighboring residues Val309 and Gly312 form
hydrogen bonds with Val276. Tyr311-O forms a hydrogen
bond with the indole nitrogen of Trp292, and Arg310-N is
hydrated. If a trans peptide bond was modelled, there would
be no hydrogen bond donor in close enough proximity to be a
partner for Arg310-O. The second source of stabilization is
evident from Fig. 2A. The hydrophobic part of the side chain
of Arg310, namely CL and CQ , packs against the aromatic ring
of Tyr311 at a distance of less than 3.5 Aî , which is too short
for a simple van der Waals interaction.
A similar situation was observed for the cis peptide bond
between Gln425 and Phe426. Gln425-O forms a water-mediated
hydrogen bond with Ser413-N (Fig. 3B) and Phe426-N is hy-
drogen bonded to Pro411-O. Pro411 is itself involved in a cis
peptide bond with Gly410. Gln425-N is hydrated by a water
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Table 2
Data collection and re¢nement statistics
Data collection
Number of crystals 5
Resolution limits (Aî ) 100^2.1
Total number of re£ections 293 385
Unique re£ections 89 672
Completeness (%) 81.6
Rmerge (%)a 10.3
Rr:i:m: (%)b 12.0
Rp:i:m: (%)c 5.9
Re¢nement
Resolution limits (Aî ) 40^2.1
Data cuto¡ [F/c(F)] 0.0
Number of re£ections 89 649
Working set 87 854
Test set 1795
R (%)d 18.3
Rfree (%) 23.6
# Protein atoms 11 556
# Solvent atoms 487
Average B-factor (Aî 2) 39.7
R.m.s.d. bonds (Aî ) 0.010
R.m.s.d. angles (‡) 1.562
aRmerge 
P
hkl
P
i MIihkl3IhklM=
P
hkl
P
i Iihkl, where (hkl) de-
notes the sum over all re£ections and (i) the sum over all equivalent
and symmetry-related re£ections [29].
bRr:i:m: is the redundancy-independent merging R-factor [11].
Rr:i:m: 
X
hkl

N
N31
r X
i
MIihkl3IhklM=
X
hkl
X
i
Iihkl
with N being the number of times a given re£ection has been ob-
served.
cRp:i:m: is the precision-indicating merging R-factor [11].
Rp:i:m: 
X
hkl

1
N31
r X
i
MIihkl3IhklM=
X
hkl
X
i
Iihkl:
dR=ghkl MFobs3kWFcalc M/ghkl Fobs.
Fig. 3. Schematic representation of the main-chain interactions of
the segments Arg310^Tyr311 (A) and Gln425^Phe426 (B). The distan-
ces are measured from subunit 1 atoms and are given in Aî . In (B)
atoms of the second subunit are marked by P.
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molecule located on the local twofold rotation axis, connect-
ing the two Gln425 residues in the dimer. With a trans peptide
bond present there would be no hydrogen bonding partner for
Phe426-O. Also in this case, side chain stacking is observed.
The hydrophobic part of the glutamine side chain (CL and CQ )
packs against the aromatic ring of Phe426 at a distance of less
than 3.7 Aî (see also Fig. 2B).
A sequence alignment between the factor XIII domain 2
sequence and several transglutaminase enzymes from the
Swissprot database is presented in Fig. 4. The overall se-
quence identity in this about 300 amino acid-long stretch
ranges between 33 and 55%. The regions of the two cis pep-
tide bonds, shown in Fig. 4, exhibit a high degree of sequence
conservation. In region 1 all amino acids observed on the N-
terminal side of the cis peptide bond are either charged or
polar residues with long side chains except for a Cys in human
transglutaminase 4 and the aromatic residues in the homolo-
gous erythrozyte membrane protein band 4.2 (P4.2). On the
C-terminal side, only aromatic residues are observed except
for the P4.2 proteins, where the aromatic residue has been
replaced by negatively charged residues, but instead aromatic
residues occur here on the N-terminal side. The region C-
terminal to the cis peptide bond in region 1 is the active site
region, which explains the absolute conservation of these res-
idues. In region 2 as well an almost complete conservation of
aromatic residues on the C-terminal side of the cis peptide
bond can be observed except for the P4.2 proteins which
contain proline residues at this site. On the N-terminal side
again mostly long polar side chains are observed although
slightly less pronounced than in region 1. Furthermore, the
Gly410^Pro411 cis peptide bond seems to be conserved as well,
as shown by the absolute conservation of the sequence GlyPro
at this site in all transglutaminases. In the P4.2 proteins the
proline is shifted two residues towards the C-terminus in the
alignment (data not shown). These observations corroborate
the notion that cis peptide bonds do also occur in all other
transglutaminases at these sites and in the P4.2 proteins as
well.
4. Discussion
The major problem in understanding the function of factor
XIII to date is the activation process. The identi¢ed catalytic
centre comprising residues Cys314, His373 and Asp396 is com-
pletely buried and therefore unaccessible to the substrate. The
activation process includes the cleavage of the scissile peptide
bond between Arg37 and Gly38, but that alone is not su⁄cient
to expose the active site as was seen in the structural analysis
of thrombin-cleaved factor XIIIaP [7]. The activation peptide
did not dissociate spontaneously from the rest of the protein,
which in retrospect is not surprising considering the estimated
interaction energy of about 314 kcal/mol and a total buried
surface area of 3700 Aî 2.
Even after the hypothetical removal of the activation pep-
tide the active site is still practically unaccessible. In order to
expose the active site, domains 2 and 3 need to be separated
from each other. This would leave the active site at least
partially accessible, which may be enough for catalysis to
occur. The problem is, however, how a tight interaction
such as the one between domains 2 and 3 (311 kcal/mol or
3000 Aî 2 buried surface area) can be broken. The extent of this
interaction compares with the one found at the interface of
stable oligomeric proteins. According to Janin et al. [23], in a
stable oligomer a minimum buried surface of 1200 Aî 2 is re-
quired to overcome the entropy loss upon association. It has
been speculated that binding of factor XIII to either the ¢brin
substrate or some other e¡ector, possibly calcium, could trig-
ger the conformational rearrangement necessary for exposing
the active site.
In the X-ray structure of the enzyme in the presence of
calcium [24], a binding site for the metal ion has been de-
tected, but no structural changes other than small local rear-
rangements of the calcium-binding amino acids were ob-
served. Based on this evidence we conclude that calcium
ions alone cannot be responsible for the activation process
to occur.
Another possible explanation is that binding to the sub-
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Fig. 4. Sequence alignment of human factor XIII with representative transglutaminases in the regions of the cis peptide bonds. The code given
is the SWISSPROT database code, and the identity is with respect to the alignment against factor XIII. The number of amino acids denotes
the total length of the aligned region. The residues directly £anking the cis peptide bonds are inside the boxes.
M.S. Weiss et al./FEBS Letters 423 (1998) 291^296 295
strate ¢brin will cause the active site to become exposed.
However, if the energy necessary to break the interaction be-
tween domains 2 and 3 is provided by the binding of ¢brin,
then one tight interaction will be replaced by another and the
dissociation problem will just be shifted one step down the
line. Moreover, factor XIII is also activated by small sub-
strates like peptides [25], binding of which will not provide
such large energies. This underlines the importance of a mech-
anism of activation that is more independent of binding to
substrate than has been previously suggested.
Based on our results, we propose that the protein has an
inherent ability to assume two conformational states, and that
a cis/trans isomerization of the peptide bonds Arg310^Tyr311,
Gln425^Phe426 and Gly410^Pro411 may act as a conformational
switch between these two states. If one or all of the bonds
isomerize to the energetically favored trans conformation, lo-
cal strain along the chain will build up. This could be the
trigger for a conformational rearrangement, which leads to
a reduction of the binding energy between domains 2 and 3
or even in a partial separation of the two. The remaining
energy necessary for exposing the active site could then be
provided by substrate binding.
The fact that non-proline cis peptide bonds are very rare in
protein structures [26] and that the ones described here are
found in such peculiar locations (one close to the active site
and the other at the dimerization interface in a cluster with a
second cis peptide bond) strongly suggests a functional role
for them. Furthermore, the cis peptide bonds are likely to be
conserved within the family of transglutaminases, which sup-
ports this hypothesis.
Site-directed mutagenesis of either Arg310 or Tyr311 to Ala
[27] reduced the enzymatic activity dramatically, without re-
ducing the binding to ¢brin. Especially the Y311A mutation
yielded an enzyme without any detectable activity. This also
supports our hypothesis of ascribing functional importance to
these residues. To our knowledge there have been no point
mutations in the region of the second cis peptide bond de-
scribed so far, but we predict that mutating either Gln425 or
Phe426 will a¡ect the function of factor XIII in a similar fash-
ion.
In summary, we have presented a well-re¢ned structure of
cFXIII at high resolution, we have discovered two non-pro-
line cis peptide bonds in peculiar locations, and we have pre-
sented a plausible mechanism of factor XIII activation, which
involves the cis/trans isomerization of the non-proline cis pep-
tide bonds. We will continue to investigate this mechanism by
crystallographic and other means.
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